Amplification of MDM2, a crucial molecular marker, is key to distinguishing benign lipomas and their variants from locally aggressive counterparts such as atypical lipomatous tumors and well-differentiated liposarcomas [5]. This evidence concerns the gene MDM2 and atypical lipomatous tumor.